Telomir Pharmaceuticals (NASDAQ:TELO) Shares Up 0.8% – Still a Buy?

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) shot up 0.8% on Friday . The stock traded as high as $1.27 and last traded at $1.24. 53,204 shares traded hands during mid-day trading, a decline of 63% from the average session volume of 145,492 shares. The stock had previously closed at $1.23.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a report on Tuesday, April 21st. Zacks Research upgraded Telomir Pharmaceuticals to a “hold” rating in a research note on Wednesday, March 18th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Telomir Pharmaceuticals has an average rating of “Hold”.

Telomir Pharmaceuticals Stock Performance

The company has a market cap of $85.28 million, a P/E ratio of -4.28 and a beta of -0.24. The business’s fifty day moving average is $1.30 and its two-hundred day moving average is $1.30.

Telomir Pharmaceuticals (NASDAQ:TELO) last issued its earnings results on Thursday, May 14th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC raised its position in Telomir Pharmaceuticals by 14.0% during the 4th quarter. Geode Capital Management LLC now owns 223,549 shares of the company’s stock valued at $297,000 after purchasing an additional 27,519 shares in the last quarter. Raymond James Financial Inc. lifted its holdings in shares of Telomir Pharmaceuticals by 4,101.9% in the 3rd quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock worth $105,000 after buying an additional 73,547 shares during the period. Jane Street Group LLC purchased a new stake in shares of Telomir Pharmaceuticals in the 2nd quarter worth $62,000. Marshall Wace LLP bought a new position in shares of Telomir Pharmaceuticals during the 2nd quarter worth $95,000. Finally, World Investment Advisors bought a new position in shares of Telomir Pharmaceuticals during the 4th quarter worth $47,000.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.